Spinout UCL che sviluppa terapie geniche AAV mirate per l'epilessia focale refrattaria.
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Series A British EpilepsyGTx raised a $33 million Series A, with XGEN Venture and British Business Bank, to take the EPY201 gene therapy into phase 1/2a clinical trials. | $33M |